Introduction {#jcmm12829-sec-0001}
============

Homocysteine (HCy) is a thiol‐containing amino‐acid intermediate produced during the synthesis of cysteine from methionine [1](#jcmm12829-bib-0001){ref-type="ref"}. High HCy concentrations are associated with lymphocyte‐mediated inflammatory responses driven by immune mediators [2](#jcmm12829-bib-0002){ref-type="ref"}, [3](#jcmm12829-bib-0003){ref-type="ref"}, [4](#jcmm12829-bib-0004){ref-type="ref"}. HCy metabolism is also linked to the metabolism of adenosine [5](#jcmm12829-bib-0005){ref-type="ref"}, [6](#jcmm12829-bib-0006){ref-type="ref"}, a nucleoside that potently alters lymphocyte viability *via* activation of its A~2A~ receptor (A~2A~R) [7](#jcmm12829-bib-0007){ref-type="ref"}. Adenosine has therefore an anti‐inflammatory activity [8](#jcmm12829-bib-0008){ref-type="ref"} particularly during hypoxia/ischaemia where it is produced in large amounts at the sites of injury [9](#jcmm12829-bib-0009){ref-type="ref"}.

Hyperhomocysteinaemia results from genetic enzymatic deficiencies and/or nutritional defects that affect HCy metabolism [10](#jcmm12829-bib-0010){ref-type="ref"}. Under basal conditions, adenosine and HCy result from hydrolysis of *S*‐adenosylhomocysteine (SAH) *via* the SAH hydrolase, and in hyperhomocysteinaemia conditions the hydrolase reaction reverses and SAH accumulates at the expense of adenosine. Subsequently, facilitated diffusion of plasma adenosine into the cell through equilibrative nucleoside transporters [11](#jcmm12829-bib-0011){ref-type="ref"} increases and the adenosine depletion generated by this situation reduces stimulation of its cell surface receptors [12](#jcmm12829-bib-0012){ref-type="ref"}. This situation could contribute to pathological processes [5](#jcmm12829-bib-0005){ref-type="ref"} by interfering, for example, with cardioprotective, vasodilatory effects resulting from A~2A~R activation [13](#jcmm12829-bib-0013){ref-type="ref"}, [14](#jcmm12829-bib-0014){ref-type="ref"} and several epidemiological studies showed that high concentrations of HCy are indeed associated with cardiovascular diseases [15](#jcmm12829-bib-0015){ref-type="ref"}, [16](#jcmm12829-bib-0016){ref-type="ref"}, [17](#jcmm12829-bib-0017){ref-type="ref"}.

Hydrogen sulphide, an end product of HCy catabolism *via* the transsulfuration pathway, entered recently the family of gasotransmitters along with NO and CO, because of the effects of H~2~S at the cellular and molecular level [18](#jcmm12829-bib-0018){ref-type="ref"}. This gas was also considered as an autocrine/paracrine T‐lymphocyte activator [19](#jcmm12829-bib-0019){ref-type="ref"}, and we recently reported that H~2~S reverses the adenosinergic alteration of T‐lymphocyte viability *via* repression of the NF‐κB**,** which down‐regulates A~2A~R expression [20](#jcmm12829-bib-0020){ref-type="ref"}.

Based on this finding and on the literature reported above, we undertook to delineate the relationship between HCy, adenosine and A~2A~R expression in hypoxic conditions with particular emphasis on the effects of H~2~S produced by high HCy levels on the hypoxia‐induced, adenosine‐mediated (hypoxia‐adenosinergic thereafter) signalling in lymphocytes.

Materials and methods {#jcmm12829-sec-0002}
=====================

Peripheral blood lymphocyte (PBL) preparation {#jcmm12829-sec-0003}
---------------------------------------------

Blood samples were collected from brachial vein of three healthy donors (two males and one female, 25, 38 and 42 years old respectively) after written consent. The study methodologies conformed to the standards set by the Declaration of Helsinki. Peripheral blood lymphocyte were isolated according to manufacturer\'s instructions using the Vacutainer^®^ Cell Preparation Tube density gradient system (Beckton Dickinson, Franklin lakes, NJ, USA). Cells (3 × 10^6^ cells/ml) were then incubated in the Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 2 mM [l]{.smallcaps}‐glutamine, 10% foetal calf serum and penicillin/streptomycin (100 U/ml, 100 μg/ml) for 1 hr at 37°C under 5% CO~2~ in a 25 cm^2^ flask (10 ml/flask). Adherent monocytes were then discarded and PBL present in culture supernatant were examined using the cell viability assay described below.

Cell viability assay {#jcmm12829-sec-0004}
--------------------

Peripheral blood lymphocyte and CEM cells, a human lymphoma CD4^+^ T‐cell line expressing A~2A~R [21](#jcmm12829-bib-0021){ref-type="ref"}, were cultured in RPMI 1640 medium as described above. Cell viability was monitored in 24‐well plates using the 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2H‐tetrazolium bromide (MTT) assay. The MTT assay produces a yellowish solution that is converted to dark blue, water‐insoluble, MTT formazan by oxidoreductase enzymes of living cells [22](#jcmm12829-bib-0022){ref-type="ref"}. MTT (0.5 mg in 100 μl of PBS, pH 7.3) was added to each well containing cells (0.5 × 10^6^ cells/ml) 3 hr prior to the end of the 24‐hr incubation period in culture medium containing 50--800 μM CoCl~2~ in the presence of phorbol myristate acetate (PMA, 50 ng/ml) and phytohemagglutinin (PHA, 5 μg/ml) as previously reported [20](#jcmm12829-bib-0020){ref-type="ref"}. Using the same procedure, we tested the effect of HCy by incubating cells in a medium containing PMA + PHA and 50--400 μM HCy that were added just prior to incubation with 100 μM CoCl~2~ (*i.e*. the ED~50~ deduced from the previous experiment). In subsequent tests, and prior to the addition of CoCl~2~, cells in the culture medium containing PMA + PHA were treated using 200 μM HCy (*i.e*. the maximal effective dose) and 2.5--10 mM DL‐propargylglycine (PPG). All the reagents were titrated individually in terms of activity in preliminary experiments to determine a range of active concentrations that were not cytotoxic. After treatment, cells were pelleted (10,000 × *g* for 15 min.) and supernatants were discarded. The insoluble violet formazan crystals contained in the cell pellets were dissolved using 1 ml 100% dimethyl sulfoxide and absorbance (*A*) was measured at 550 nm.

Cell culture experiments {#jcmm12829-sec-0005}
------------------------

CEM cells (0.5 × 10^6^ cells/ml) were seeded in 75‐cm^2^ flasks (50 ml/flask) and stimulated using PMA + PHA as above. The hypoxic injury was achieved by adding 100 μM CoCl~2~ to the culture medium for 24 hr. To test the effect of HCy, cells were treated by adding 200 μM HCy just prior to the addition of CoCl~2~. To test the effect of 10 mM PPG on cells treated with HCy, the reagent was added concomitantly to HCy. In preliminary experiments, effective doses of CoCl~2~, HCy and PPG were determined using the cell viability assay described below. All the drugs were added rapidly and sequentially as follows: PMA + PHA, HCy, PPG and, *in fine*, CoCl~2~ whose presence triggered the hypoxia reaction. After 24‐hr incubation in one of the following conditions (PMA + PHA containing culture medium only, idem + CoCl~2~, +CoCl~2~ and HCy, +CoCl~2~, HCy and PPG), living cells were counted using the Trypan Blue dye exclusion method, aliquoted and centrifuged (1000 × *g* for 5 min.). Cell pellets were then frozen at −80°C until use. All reagents were from Sigma‐Aldrich (St. Louis, MO, USA).

A~2A~R expression {#jcmm12829-sec-0006}
-----------------

A~2A~R expression was assessed using a semi‐quantitative Western blot procedure described previously [23](#jcmm12829-bib-0023){ref-type="ref"}. Briefly, cell pellets were lysed using a 4% sodium dodecyl sulphate aqueous solution supplemented with a protease inhibitor cocktail (Sigma‐Aldrich) and a 15 min.‐sonication treatment at 47 kHz. Cell lysates (0.5 × 10^6^) were diluted in loading buffer (65.2 mM Tris‐HCl buffer, pH 8.3, containing 10% glycerol, 0.01% bromophenol blue and 5% 2‐mercaptoethanol). Samples were then analysed using 12% sodium dodecyl sulphate‐polyacrylamide gel electrophoresis and electroblotting onto polyvinylidene difluoride membrane. Blots were incubated for 20 min. with an anti‐A~2A~R mouse mAb (Adonis; 1 μg/ml) [24](#jcmm12829-bib-0024){ref-type="ref"}; an anti‐β actin mAb (clone AC‐15, Sigma‐Aldrich; 0.5 μg/ml) was used as total protein loading control. Blots were then processed using horseradish peroxidase‐labelled antimouse antibodies and chemiluminescent substrate (SuperSignal West Femto; Pierce Biotechnology, Rockford, IL, USA). Densitometry analysis of the A~2A~R band at 45 kDa was performed with a Kodak Image Station 440CF (Eastman Kodak Company, Rochester, NY, USA) and the ImageJ software (NIH). Results were expressed as arbitrary units (AU) defined as pixels of one peak versus the sum of peaks (percent).

Adenosine and inosine assays {#jcmm12829-sec-0007}
----------------------------

Intracellular adenosine and inosine concentrations were measured as previously described [25](#jcmm12829-bib-0025){ref-type="ref"} using a high performance liquid chromatography system equipped with a diode array detector (Chromsystems, Munich, Germany). To prevent adenosine degradation, pellets of frozen cells (3 × 10^6^) were mixed with 500 μl of a cold stop solution \[0.2 mM dipyridamole, 4.2 mM ethylenediaminetetraacetic acid, 5 mM erythro‐9‐(2‐hydroxy‐3‐nonyl) adenine, 79 mM α‐β methylene adenosine 5′diphosphates and 1 IU/mL heparin sulphate in NaCl 0.9%\]. Proteins were precipitated using 1 N perchloric acid and the supernatant was injected into a LiChrospher C18 column (Merck, Darmstad, Germany). Adenosine and inosine were identified in the same run by their elution time and spectrum. Measurements were made by comparison of peak areas versus those obtained using adenosine and inosine standard solutions. The intra‐assay and interassay coefficients of variation ranged from 1% to 3% for both products.

Adenosine deaminase (ADA) activity {#jcmm12829-sec-0008}
----------------------------------

Adenosine deaminase activity was measured as previously described [23](#jcmm12829-bib-0023){ref-type="ref"}. Briefly, cells (1.5 × 10^6^) were lysed using 250 μl of ultra‐pure water, mixed with 750 μl of 28 mM adenosine in 0.9% NaCl and incubated for 36 min. at 37°C. The reaction was stopped by immersion of the samples in ice water. Ammonium production resulting from adenosine degradation by ADA was determined using a Synchron LX 20 analyser (Beckman Coulter Inc., Villepinte, France). The intra‐assay and interassay coefficients of variation ranged from 3% to 5%.

HCy and SAH assays {#jcmm12829-sec-0009}
------------------

HCy and SAH concentrations in cell pellets were measured using dedicated ELISA kits (Cusabio, Wuhan Huamei Biotech Co., Ltd, Wuhan, Hubei Province, China). These assays use a quantitative sandwich enzyme immunoassay technique where HCy or SAH are trapped onto an antibody‐coated plate prior to detection using a biotin‐conjugated antibody specific for HCy or SAH and an avidin‐conjugated horseradish peroxidase. For these assays, 2.5 × 10^6^ and 0.5 × 10^6^ cells for HCy and SAH, respectively, were lysed using 100 μl of 0.25% dodecyl trimethyl ammonium bromide in the assay buffer prior to transfer to microplate according to manufacturer\'s instructions.

H~2~S assay {#jcmm12829-sec-0010}
-----------

H~2~S production by cells was measured using the methylene blue method following trapping of the sulphides present in the culture medium using zinc acetate in alkaline conditions [26](#jcmm12829-bib-0026){ref-type="ref"}. Briefly, culture supernatants (50 ml; 0.5 × 10^6^ cells/ml) were mixed with 0.5 g of Zn acetate and 630 μl NaOH 10 N prior to centrifugation at 3000 × *g* for 10 min. The supernatants were removed by decantation and the Zn sulphide pellets were washed once with 25 ml ultra‐pure water. The pellets were then suspended in 1 ml ultra‐pure water and vigorously shaken. One hundred microlitres of 20 mM N,N dimethyl‐*p*‐phenylenediamine sulphate in 7.2 N HCl was then added followed by 100 μl of 30 mM FeCl~3~ in 1.2 N HCl and the tubes were shaken again. After 20 min. incubation at room temperature in the dark, the samples were centrifuged and the resulting methylene blue dye in the supernatant was measured at 670 nm. The calibration curve of absorbance versus sulphide concentration was obtained using known concentrations of NaHS, a H~2~S donor. The H~2~S concentration was taken as 30% of the NaHS concentration in the calculation [27](#jcmm12829-bib-0027){ref-type="ref"}.

3′, 5′‐cyclic AMP (cAMP) assay {#jcmm12829-sec-0011}
------------------------------

The concentrations of cAMP present in cell pellets were measured using the Amersham Biotrak kit (GE Healthcare Life Sciences, Buckinghamshire, UK) that combines the use of a peroxidase‐labelled cAMP conjugate and a specific antiserum immobilized on microplates. Cells (1 × 10^6^) were lysed using 100 μl of 0.25% dodecyl trimethyl ammonium bromide in the assay buffer prior to transfer to microplate wells to carry out the competitive enzyme immunoassay according to manufacturer\'s instructions.

Statistical analysis {#jcmm12829-sec-0012}
--------------------

Each assay performed in duplicate was repeated three times. Data (mean ± S.D.) were compared using the one‐way [anova]{.smallcaps} with the Fisher\'s least significant difference test. Differences with *P* \< 0.05 were considered to be statistically significant.

Results {#jcmm12829-sec-0013}
=======

HCy prevents the hypoxia‐induced alteration of lymphocyte viability {#jcmm12829-sec-0014}
-------------------------------------------------------------------

Freshly isolated PBL were used to address the authentic cell situation, whereas the human lymphoma T‐cell line CEM was used because it constitutes a cell material whose characteristics are well documented and stable. We mimicked classically the inflammatory context using PMA (5 μg/ml) and PHA (50 ng/ml), and we reproduced the hypoxia‐induced effects using a 50--800 μM CoCl~2~ treatment, a widely used method preventing HIF‐1α degradation [28](#jcmm12829-bib-0028){ref-type="ref"}, [29](#jcmm12829-bib-0029){ref-type="ref"} that was recently validated in much detail in this exact cellular model [20](#jcmm12829-bib-0020){ref-type="ref"}. CoCl~2~ also mimics hypoxia/ischaemia responses by inducing oxidative stress and inflammation [30](#jcmm12829-bib-0030){ref-type="ref"}, [31](#jcmm12829-bib-0031){ref-type="ref"}, [32](#jcmm12829-bib-0032){ref-type="ref"}, [33](#jcmm12829-bib-0033){ref-type="ref"}. Various parameters (cell density, CoCl~2~ concentration, treatment duration) were tested in preliminary experiments (data not shown) using the MTT assay to determine the conditions used subsequently. We then choose a low cell density (0.5 × 10^6^ cells/ml) to avoid cell confluency during the experiment, and a long time exposure (24 hr) to drugs (CoCl~2~, HCy, PPG) to mimic a chronic situation. As previously obtained with more cells and a shorter time [20](#jcmm12829-bib-0020){ref-type="ref"}. Figure [1](#jcmm12829-fig-0001){ref-type="fig"} shows that CoCl~2~ treatment affected in a dose‐dependent manner the viability of resting PBL (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}A) and CEM cells (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}B), PMA + PHA stimulation further increasing the CoCl~2~ effect. We next tested the effect of 50--400 μM HCy on lymphocyte viability in a PMA + PHA‐containing culture medium in the presence, or in the absence, of CoCl~2~. A 100 μM CoCl~2~ concentration was chosen to mimic hypoxic conditions because it corresponded to the concentration that reproducibly induced the half‐maximal effect on stimulated PBL (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}A) and CEM cell (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}B) viability. In the absence of CoCl~2~, HCy did not affect cell viability, whereas the effect resulting from CoCl~2~ treatment for 24 hr was reversed in a dose‐dependent manner using HCy in PBL (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}C) and CEM cell cultures (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}D). We previously obtained similar results using NaHS, a H~2~S donor [20](#jcmm12829-bib-0020){ref-type="ref"}.

![Cell viability following CoCl~2~‐ and HCy‐treatments. The viability index of PBL (**A**) and CEM cells (B), resting or stimulated using PMA+PHA and incubated with 50--800 μM CoCl~2~ for 24 hr was monitored using the MTT assay. Incubation with 50--400 μM HCy in the presence, or not, of 100 μM CoCl~2~ was similarly tested using stimulated PBL (**C**) and CEM cells (B). The dark blue dye produced by living cells was spectrophotometrically measured. Data are given as *A* ~550\ nm~ value (mean ± S.D., *n* = 3).](JCMM-20-1411-g001){#jcmm12829-fig-0001}

These data indicate that high HCy levels promoted lymphocyte survival in hypoxic conditions, and we used subsequently the maximal effective concentration (200 μM) of HCy.

PPG modulation of HCy effect {#jcmm12829-sec-0015}
----------------------------

PPG is a specific inhibitor of cystathionine‐γ‐lyase (CSE), and consequently an agent that represses the CSE‐mediated H~2~S production [34](#jcmm12829-bib-0034){ref-type="ref"}. To address the mode of action of HCy, we examined using 2.5--10 mM PPG whether HCy acted *via* its degradation product H~2~S that down‐regulates A~2A~R expression [20](#jcmm12829-bib-0020){ref-type="ref"}. Using a high concentration (200 μM) of HCy, and in a context mimicking chronic hypoxia (24 hr incubation with 100 μM CoCl~2~), PPG treatment decreased in a dose‐dependent manner the viability of stimulated PBL (Fig. [2](#jcmm12829-fig-0002){ref-type="fig"}A) and CEM cells (Fig. [2](#jcmm12829-fig-0002){ref-type="fig"}B) versus the 'hypoxia + hyperhomocysteinemia' condition.

![Effect of PPG in hypoxia and hyperhomocysteinaemia conditions. PMA+PHA‐stimulated PBL (**B**) and CEM cells (**B**) treated with 100 μM CoCl~2~ and 200 μM HCy for 24 hr were incubated with 2.5--10 mM PPG. The viability index was monitored using the MTT assay. Data are given as *A* ~550\ nm~ value (mean ± S.D., *n* = 3). Controls were cells incubated with/without 100 μM CoCl~2~ and/or 200 μM HCy. Statistical significance (*P* \< 0.05) was indicated by brackets where applicable.](JCMM-20-1411-g002){#jcmm12829-fig-0002}

These data suggest that the effect of HCy on cell viability was reversed by CSE inhibition, and resulted therefore from H~2~S production. To further delineate this mechanism, we used in the next experiments the highest concentration of PPG (10 mM) we tested.

Adenosine metabolism {#jcmm12829-sec-0016}
--------------------

In hypoxic conditions, adenosine is produced intracellularly from ATP and can be secreted *via* equilibrative nucleoside transporters [35](#jcmm12829-bib-0035){ref-type="ref"}. In the cell, adenosine can be degraded into inosine by ADA. Adenosine can be also produced in the extracellular environment by the ectoATPase/apyrase CD39 and ectonucleotidase CD73 [36](#jcmm12829-bib-0036){ref-type="ref"} prior to its degradation by ADA associated at the cell surface *via* CD26 [37](#jcmm12829-bib-0037){ref-type="ref"}. In lymphocyte population, extracellular adenosine can be produced from ATP by the CD4^+^, CD25^+^ regulatory T cells that express both CD39 and CD73 at high levels [38](#jcmm12829-bib-0038){ref-type="ref"}.

Here, we focused on the intracellular adenosine metabolism by testing adenosine and inosine levels as well as ADA activity in lysates of stimulated CEM cells cultured in various conditions. The results are given in Figure [3](#jcmm12829-fig-0003){ref-type="fig"}A: (*i*) CoCl~2~ treatment induced a rise in cellular concentrations of adenosine and inosine (4.17 *versus* 2.68 μM and 9.09 *versus* 2.67 μM in basal conditions respectively), the latter resulting probably from the increase in ADA activity (6.68 *versus* 3.03 IU) produced to counteract the elevated adenosine production generated by hypoxia; (*ii*) a treatment combining CoCl~2~ and HCy tended to further increase the concentration of adenosine generated by hypoxia (5.50 *versus* 4.17 μM in hypoxia) while ADA activity and the resulting inosine concentration decreased (2.99 *versus* 6.68 IU and 8.23 *versus* 9.09 μM respectively); (*iii*) a treatment combining CoCl~2~ and HCy together with PPG to inhibit H~2~S produced *via* HCy catabolism did not modify adenosine concentration (5.32 *versus* 5.50 μM in the 'hypoxia + hyperhomocysteinemia' condition) but increased inosine production (13.10 *versus* 8.23 μM), a result which was consistent with the parallel increase in ADA activity (6.32 *versus* 2.99 IU).

![Metabolism of adenosine and HCy; adenosinergic signalling. Intracellular adenosine/inosine concentrations, as well as ADA activity, were measured in cell lysates (**A**). Intracellular SAH and HCy concentrations were measured in cell lysates, H~2~S being measured in culture supernatants (**B**). A~2~ ~A~R expression, cAMP concentration and viability of the cells were also measured (**C**). PMA+PHA‐stimulated CEM cells were cultured for 24 hr in four experimental conditions: the 'control' condition (stimulated cells), 'hypoxia' (**+**100 μM CoCl~2~), 'hypoxia+hyperhomocysteinaemia' (**+**200 μM HCy) and 'hypoxia + hyperhomocysteinaemia' in the presence of 10 mM PPG. Results are mean ± S.D., *n* = 3. Statistical significance (*P* \< 0.05) was indicated by brackets where applicable. Specific A~2~ ~A~R bands (45 kDa) from a representative Western blot are shown in the insert.](JCMM-20-1411-g003){#jcmm12829-fig-0003}

These results suggested that the recovery of lymphocyte viability resulting from HCy treatment (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}C and D) was not because of a decreased production of adenosine since in fact its intracellular concentration increased (Fig. [3](#jcmm12829-fig-0003){ref-type="fig"}A).

HCy metabolism {#jcmm12829-sec-0017}
--------------

During the conversion of methionine to HCy, *S*‐adenosylmethionine is produced from ATP. After demethylation, SAH is generated and subsequently degraded by the SAH hydrolase into HCy and adenosine that are quickly used in basal conditions, the enzyme being also able to function in the opposite direction [39](#jcmm12829-bib-0039){ref-type="ref"}. HCy may be then remethylated to methionine or it may be condensed with serine to form cystathionine and then cysteine *via* the transsulfuration pathway [40](#jcmm12829-bib-0040){ref-type="ref"}. H~2~S, an end product of the pathway, is produced by cystathionine β‐synthase and CSE from HCy during T‐cell activation [19](#jcmm12829-bib-0019){ref-type="ref"}. In the following experiments, we focused on H~2~S production by CSE because: (*i*) CSE controls the metabolism of cysteine into H~2~S, pyruvate and NH4^+^ [41](#jcmm12829-bib-0041){ref-type="ref"}; (*ii*) CSE is the main player in hyperhomocysteinaemia conditions [42](#jcmm12829-bib-0042){ref-type="ref"} and iii) CSE can be specifically inhibited using PPG [34](#jcmm12829-bib-0034){ref-type="ref"}.

The HCy metabolism in lymphocyte was studied by testing HCy and SAH concentrations in lysates of stimulated CEM cells cultured in various conditions while H~2~S intracellularly produced and subsequently secreted in the culture medium was measured in the culture supernatant. Our findings are given in Figure [3](#jcmm12829-fig-0003){ref-type="fig"}B: (*i*) following CoCl~2~ treatment, HCy and hence H~2~S concentration, decreased *versus* basal conditions (3.01 *versus* 3.59 μM and 0.81 *versus* 1.01 μM respectively). Conversely, SAH production increased (4.47 *versus* 4.07 μM) as a result of the hypoxia‐induced production of adenosine; (*ii*) a treatment combining 100 μM CoCl~2~ and 200 μM HCy in the culture medium markedly increased intracellular HCy concentration (4.63 *versus* 3.01 μM in hypoxia); this situation stimulated intracellular SAH production (5.34 *versus* 4.47 μM), which in turn promoted HCy degradation *via* the transsulfuration pathway into H~2~S that strongly increased in culture medium (1.31 *versus* 0.81 μM); (*iii*) a treatment combining CoCl~2~, HCy and PPG did not significantly alter the concentration of SAH and HCy (5.03 *versus* 5.34 μM and 4.61 *versus* 4.63 μM in the 'hypoxia + hyperhomocysteinaemia' condition respectively) but strongly decreased H~2~S production (0.71 *versus* 1.31 μM).

These data further support the conclusion that hyperhomocysteinaemia reversed the hypoxia‐adenosinergic alteration of lymphocyte viability *via* H~2~S production.

Adenosinergic signalling {#jcmm12829-sec-0018}
------------------------

Adenosine inhibits lymphocyte viability mainly *via* A~2A~R signalling and stimulation of adenylyl‐cyclase and G~S~‐proteins [43](#jcmm12829-bib-0043){ref-type="ref"}, [44](#jcmm12829-bib-0044){ref-type="ref"}, which controls in turn a plethora of biological processes [45](#jcmm12829-bib-0045){ref-type="ref"}. We addressed here the hypoxia‐adenosinergic lymphocyte signalling by testing A~2A~R expression, cAMP production and viability of stimulated CEM cells cultured in various conditions. The data are given in Figure [3](#jcmm12829-fig-0003){ref-type="fig"}C: (*i*) CoCl~2~ treatment increased A~2A~R expression and cAMP production compared with the basal situation (24.0 *versus* 19.1 AU and 1902 *versus* 643 fmol/well respectively). This result reflected the binding of adenosine produced by the cell to an increasing number of A~2A~R, which decreased lymphocyte viability as shown using the MTT assay (*A* ~550\ nm~ = 0.56 *versus* 2.11 in the basal conditions); (*ii*) a treatment combining CoCl~2~ and HCy reversed the inhibitory effect on viability (*A* ~550\ nm~ = 1.53 *versus* 0.56 in hypoxia) by decreasing A~2A~R expression and the resulting cAMP production (18.6 *versus* 24.0 AU and 947 *versus* 1902 fmol/well respectively); (*iii*) a treatment combining CoCl~2~, HCy and PPG prevented the effect of HCy and increased A~2A~R expression as well as cAMP production (21.2 *versus* 18.6 AU and 1638 *versus* 947 fmol/well in the 'hypoxia + hyperhomocysteinaemia' condition respectively), cell viability decreasing (*A* ~550\ nm~ = 0.75 *versus* 1.53) to a value close to that found in the 'hypoxia' condition (*A* ~550\ nm~ = 0.56).

These results indicate that the loss of the hypoxia‐adenosinergic alteration of lymphocyte viability observed in the presence of HCy (Fig. [1](#jcmm12829-fig-0001){ref-type="fig"}C and D) mainly depended on the decreased level of A~2A~R expression (Fig. [3](#jcmm12829-fig-0003){ref-type="fig"}C) resulting from H~2~S production (Fig. [3](#jcmm12829-fig-0003){ref-type="fig"}B).

Discussion {#jcmm12829-sec-0019}
==========

We found here that in CoCl~2~‐induced hypoxic conditions, high HCy levels increased H~2~S production, which down‐regulated A~2A~R expression and repressed the potent hypoxia‐adenosinergic alteration of lymphocyte viability. We performed preliminary experiments in which the monitoring of cell viability was used to dissect HCy regulation of hypoxia‐adenosinergic signalling in lymphocytes. We conducted four experimental conditions in culture medium supplemented with PMA + PHA: the control situation, hypoxia, hypoxia and hyperhomocysteinaemia, and hypoxia and hyperhomocysteinaemia in the presence of PPG. We previously reported using the same CEM cell line that hypoxia stimulates adenosinergic signalling [23](#jcmm12829-bib-0023){ref-type="ref"} and that A~2A~R stimulation decreases lymphocyte viability [20](#jcmm12829-bib-0020){ref-type="ref"}, [21](#jcmm12829-bib-0021){ref-type="ref"}. Here, we confirmed these previous data and detailed the metabolic pathways of HCy and adenosine that are interdependent and involved in the control of lymphocyte viability (see Fig. [4](#jcmm12829-fig-0004){ref-type="fig"} for an overview).

![Proposed overview of HCy modulation of the adenosinergic signalling in lymphocytes. Four experimental cell culture conditions are considered: the 'control' condition (PMA+PHA‐stimulated cells) (1), 'hypoxia' (2), 'hypoxia+hyperhomocysteinaemia' (3) and 'hypoxia+hyperhomocysteinaemia' in the presence of PPG (4). Up/down arrows represent the increase/decrease in a parameter respectively. The thickness of the arrow reflects the level of the parameter. CoCl~2~‐mediated hypoxia induces intracellular production of adenosine that can exit the cell through equilibrative nucleoside transporters. Adenosine stimulates A~2~ ~A~R that triggers the cAMP‐mediated suppressive signal. HCy is added to the cell medium. H~2~S is produced from HCy by CSE that is inhibited by PPG. H~2~S represses ADA production and A~2~ ~A~R expression.](JCMM-20-1411-g004){#jcmm12829-fig-0004}

Firstly, we found that hypoxia increased intracellular adenosine concentration to form SAH at the expense of HCy *via* the SAH hydrolase. In basal conditions, the hydrolase tends to produce adenosine and HCy from SAH because these products are rapidly catabolized [39](#jcmm12829-bib-0039){ref-type="ref"}. Under hypoxic conditions, intracellular adenosine synthesis increases, which results in a shift of the enzymatic reaction towards SAH production from adenosine and HCy as shown here. A major consequence is that HCy is no longer catabolized to form H~2~S, and this situation prevents the known down‐regulation of adenosinergic signalling by H~2~S [20](#jcmm12829-bib-0020){ref-type="ref"}. Taking into account that lymphocytes, in particular T lymphocytes, play a pivotal role in interaction with other immune cells such as monocytes and neutrophils in an inflammatory context, repressing the lymphocyte response in hypoxic condition can contribute to the protective effect of A~2A~R activation, notably in cardiovascular disease [46](#jcmm12829-bib-0046){ref-type="ref"}. In the heart, it is also noteworthy that production of adenosine following hypoxia/ischaemia has positive effects on the vasculature *via* the A~2A~R‐mediated coronary vasodilation process [47](#jcmm12829-bib-0047){ref-type="ref"}, [48](#jcmm12829-bib-0048){ref-type="ref"}, [49](#jcmm12829-bib-0049){ref-type="ref"}. Thus, during hyperhomocysteinaemia in hypoxic/ischaemic conditions, the catabolism of HCy into H~2~S and its beneficial action on lymphocyte viability may be of particular importance regarding the onset and progression of cardiovascular disorders that generally include a strong inflammatory background [15](#jcmm12829-bib-0015){ref-type="ref"}.

Secondly, when high extracellular concentrations of HCy were added to the cell environment to mimic hyperhomocysteinaemia, HCy entered the cell by transporters similar to those for cysteine and cystine [50](#jcmm12829-bib-0050){ref-type="ref"}. In these conditions, intracellular HCy was no longer the limiting substrate for the production, together with adenosine, of SAH that strongly increased. The resulting high SAH concentration then forced the SAH hydrolase‐mediated reaction to reverse and produce, as in basal conditions, HCy and adenosine that accumulated into the cell. Excess of intracellular HCy produced from SAH could be in turn degraded to generate H~2~S that repressed both ADA activity and A~2A~R expression. The resulting low ADA activity enabled to increase intracellular adenosine concentration and to decrease inosine production, whereas the low A~2A~R expression restored the lymphocyte viability.

Thirdly, we further showed that HCy reversed the suppressive effect of hypoxia on lymphocyte viability *via* its catabolism into H~2~S, PPG preventing the H~2~S inhibitory effect on both ADA activity and A~2A~R expression. In these conditions, adenosine could then exit the cell to activate the highly expressed A~2A~R that, in turn, produced high level of cAMP as in hypoxic conditions, whereas excess of intracellular adenosine was catabolized by ADA into inosine. We observed, however, that PPG did not increase intracellular homocysteine level, suggesting that homocysteine was metabolized further into cystathionine by cystathionine β‐synthase but not into the H~2~S end product that requires the CSE activity. Moreover, the increase in H~2~S production triggered by HCy was completely abolished by PPG. These data are significant as they provide additional evidence that CSE is a central player in H~2~S production in lymphocytes [41](#jcmm12829-bib-0041){ref-type="ref"}. By showing using PPG the H~2~S‐mediated hyperhomocysteinaemia effect on the hypoxia‐adenosinergic signalling in lymphocytes, we also support here the pro‐inflammatory role attributed to H~2~S [51](#jcmm12829-bib-0051){ref-type="ref"} as well as its repressive action on A~2A~R expression [20](#jcmm12829-bib-0020){ref-type="ref"}.

These results show that HCy down‐regulates A~2A~R expression in hypoxic conditions *via* H~2~S production. We propose that this mechanism has strong implications for immunosuppression, and particularly for patients with cardiovascular diseases and severe hyperhomocysteinaemia that was shown to be associated with inflammation and cardiovascular complications. Our findings may provide clues to explain why hyperhomocysteinaemia constitutes a risk factor in cardiovascular diseases [15](#jcmm12829-bib-0015){ref-type="ref"}, [16](#jcmm12829-bib-0016){ref-type="ref"}, [17](#jcmm12829-bib-0017){ref-type="ref"} and may therefore help to define new therapeutic strategies.
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